Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

340B Spotlight: Trends in shifting site of care

September 21, 2016

A new study looks at trends in health and hospital system acquisition of physician practices.

Read More

PhRMA Brings Scientists to Capitol Hill

September 21, 2016

PhRMA is bringing more than 60 researchers and scientists to meet with members of Congress to discuss shared goals.

Read More

New Survey: Patients’ share of health care costs continues to grow

September 20, 2016

Kaiser Family Foundation/Health Research & Educational Trust annual survey shows patients’ share of health care costs continues to grow.

Read More

Patient voices missing from media conversation about prescription drug abuse

September 19, 2016

The patient voice is missing from the media conversation about prescription drug abuse. Learn how PhRMA strongly supports efforts to combat opioid abuse.

Read More

Who gets a seat at ICER’s table? Hint: It’s not patients

September 19, 2016

A blog post to release a new infographic on the lack of patient representation in ICER’s leadership.

Read More

Medicare Monday: New study highlights impact of variability in Medication Therapy Management programs

September 19, 2016

New study examined more than 500 Medicare Part D plans and found wide variability in plans’ eligibility for Medication Therapy Management services.

Read More

2016 BCI Survey: A pro-innovation environment is essential for biopharmaceutical investment

September 16, 2016

In the race for biopharmaceutical investment, economies with pro-innovation policies – many of them relatively small economies – are quickening their stride.

Read More

Statement on Biosimilar User Fee Act Reauthorization

September 16, 2016

The Biosimilar User Fee Act (BsUFA) is critical to supporting the U.S. Food and Drug Administration (FDA) in its core mission of protecting public health.

Read More

Statement on Biosimilar User Fee Act Reauthorization

September 16, 2016

The Biosimilar User Fee Act (BsUFA) is critical to supporting the U.S. Food and Drug Administration (FDA) in its core mission of protecting public health.

Read More

PhRMA Statement on the United Nations High Level Panel Report on Access to Medicines

September 14, 2016

PhRMA president and CEO Stephen J. Ubl issued the following statement on today’s release of the report of the United Nations Secretary General’s High-Level Panel on Access to Medicines.

Read More
prev 1 2 3 4 5 6 next